Abstract
The current and future management of non-melanoma skin cancer (NMSC)—predominantly basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)—represents a significant public health problem worldwide. Australia has one of the highest rates of skin cancer in the world, with data showing that NMSC is five times more common than all other cancers combined [1]. The sun-exposed head and neck (HN) is the most common location, with incidence rates continuing to rise 3–10 % per year. Although BCC is more common, the vast majority of NMSCs are localized and easily treated with simple excision. However, 5 % are considered high-risk (nearly always SCC) and metastasize to regional lymph nodes with the potential for distant spread [2].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
